Ligand Total Stockholder Equity from 2010 to 2024

LGND Stock  USD 80.54  0.10  0.12%   
Ligand Pharmaceuticals' Total Stockholder Equity is increasing over the years with slightly volatile fluctuation. Overall, Total Stockholder Equity is expected to go to about 736 M this year. Total Stockholder Equity is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. View All Fundamentals
 
Total Stockholder Equity  
First Reported
1994-03-31
Previous Quarter
700.9 M
Current Value
806.5 M
Quarterly Volatility
309.4 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Ligand Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ligand Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 37.4 M, Interest Expense of 623.2 K or Total Revenue of 101.8 M, as well as many indicators such as Price To Sales Ratio of 9.2, Dividend Yield of 0.42 or PTB Ratio of 1.67. Ligand financial statements analysis is a perfect complement when working with Ligand Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Ligand Pharmaceuticals Correlation against competitors.

Latest Ligand Pharmaceuticals' Total Stockholder Equity Growth Pattern

Below is the plot of the Total Stockholder Equity of Ligand Pharmaceuticals Incorporated over the last few years. It is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. Ligand Pharmaceuticals' Total Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Ligand Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Total Stockholder Equity10 Years Trend
Slightly volatile
   Total Stockholder Equity   
       Timeline  

Ligand Total Stockholder Equity Regression Statistics

Arithmetic Mean408,327,310
Geometric Mean198,256,511
Coefficient Of Variation76.91
Mean Deviation272,758,023
Median418,647,000
Standard Deviation314,049,261
Sample Variance98626.9T
Range813M
R-Value0.93
Mean Square Error14917T
R-Squared0.86
Slope65,105,859
Total Sum of Squares1380777.1T

Ligand Total Stockholder Equity History

2024736 M
2023700.9 M
2022597.5 M
2021821.6 M
2020709.5 M
2019767.2 M
2018560.9 M

About Ligand Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Ligand Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Ligand Pharmaceuticals investors use historical funamental indicators, such as Ligand Pharmaceuticals's Total Stockholder Equity, to determine how well the company is positioned to perform in the future. Although Ligand Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Ligand Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Ligand Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Ligand Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Ligand Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Stockholder Equity700.9 M736 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Information and Resources on Investing in Ligand Stock

When determining whether Ligand Pharmaceuticals is a strong investment it is important to analyze Ligand Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ligand Pharmaceuticals' future performance. For an informed investment choice regarding Ligand Stock, refer to the following important reports:
Check out the analysis of Ligand Pharmaceuticals Correlation against competitors.
You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ligand Pharmaceuticals. If investors know Ligand will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ligand Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
1.032
Earnings Share
5.35
Revenue Per Share
6.774
Quarterly Revenue Growth
(0.30)
Return On Assets
(0)
The market value of Ligand Pharmaceuticals is measured differently than its book value, which is the value of Ligand that is recorded on the company's balance sheet. Investors also form their own opinion of Ligand Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ligand Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ligand Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ligand Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ligand Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ligand Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ligand Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.